Amgen Pharmaceutical Company Planning Developing New Osteoporosis Drug
Carolyn Thompson
Amgen NASDAQ: AMGN pharmaceutical powerhouse just announced outstanding performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.
Study met primary endpoint of Reducing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."
Denosumab is the premier fully human monoclonal antibody in late stage clinical development that particularly targets RANK Ligand, an important regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being investigated for its ability to inhibit every stage of osteoclast activity through a targeted mechanism. Denosumab is being researched for a variety of bone loss illnesses including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its ability to delay bone metastases and stop and treat bone destruction across many stages of cancer.
Often referred to as the "silent epidemic", osteoporosis is a global problem illness, which is increasing in significance as the population of the world both increases and ages. The World Health Organization (WHO) has just claimed osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical (http://www.audiolearn.net/Pharmaceutical_Drugs/Pharmaceutical_Drugs.html) industry to help combat this horrendous disease.
According to Amgen the financial burden of osteoporosis is referred to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).
Clinical pharmacist (http://www.audiolearn.net/Pharmaceutical_Drugs/Reference.html) have been developing prescriptions drugs to help patient who experience serious side effects. These products are developed almost at the same time as the medications that assist in the treatment of the initial illness. The fact that research is available to help anticipate the potential effects and interactions drugs have with one another is awesome.
These medicines are prescribed to prevent and treat osteoporosis. Some medicines slow the rate of bone loss or increase bone thickness. Even small amounts of new bone growth may reduce the risk of broken bones. It is essential that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions (http://www.audiolearn.net/Pharmaceutical_Drugs/Review.html').
|
